An MD Anderson team is among six recently named recipients of the 2017 Movember Foundation-Prostate Cancer Foundation (PCF) Challenge Awards. The $1 million awards support cross-disciplinary research to advance treatments and cures for prostate cancer.
Since 2007, the Movember Foundation has contributed more than $50 million to PCF to further new discoveries in prostate cancer research.
MD Anderson's team of Ana Aparicio, M.D., associate professor, Genitourinary Medical Oncology; Nicholas Navin, Ph.D., associate professor, Genetics, and Andrew Sabin Family Fellow; Theocharis Panaretakis, Ph.D., visiting associate professor, Genitourinary Medical Oncology; and Brian Chapin, M.D., assistant professor, Urology, will study the impact of local therapy on outcomes of men with newly diagnosed metastatic prostate cancer, within molecularly defined subsets.
Prospective clinical trials are ongoing to determine whether men with metastatic prostate cancer might benefit from surgery or radiation to their primary tumor, in addition to the standard hormonal and chemotherapy-hormonal therapies. Prostate cancer is clinically and biologically a heterogeneous disease, with certain subsets more responsive to hormonal therapies than others, says Aparicio.
"This generous donation enables our researchers to better understand the biology that underlies responsiveness to specific prostate cancer treatments, including definitive treatment of the primary tumor," she says. "It will allow us to arrive at a biologically based, predictive classification of prostate cancer that will accelerate the development of effective treatments."